Merck Surges on mRNA Cancer Vaccine Success and FDA Approvals

Merck's stock has surged 73% over the past year, thanks in part to its successful mRNA cancer vaccine trial with Moderna. The company has also received FDA approval for new drugs like LIPFENDRA, an oral cholesterol treatment.

The pipeline of innovative products at Merck is robust, with commercial potential exceeding $70 billion from more than 20 new products. This addresses concerns over the impending patent expiration of KEYTRUDA, one of the company's flagship drugs.

Despite its impressive growth, Merck trades at a relatively low 16x forward earnings multiple compared to its peers. Analysts say that the key challenge ahead is executing the commercial strategy to capitalize on these innovations and sustain growth.